NEW YORK (GenomeWeb News) – The UK’s Institute of Cancer Research will use Thermo Fisher Scientific’s proteomics technologies in an integrative network biology initiative, the company said today.
ICR will use Thermo’s TSQ Vantage triple quadrupole system, the Kingfisher Flex sample prep system, two LTQ Orbitrap Velos mass spectrometers, and other technologies, the company said.
The agreement includes lab equipment, protein reagents, mass spectrometry, RNA silencing, and related services.
The ICR team is assessing how networks of cancer cells interact with each other and surrounding tissues to metastasize throughout the body.
Chris Marshall, a professor of cell and molecular biology at ICR, said in a statement that integrating mass spectrometry data with other data, including RNAi screens, "will allow us to generate detailed models of processes such as invasion and metastasis.”
Financial terms of the agreement were not released.